Publications by authors named "Kannon Nathan"
A multi-centre survey reveals variations in the standard treatments and treatment modifications for head and neck cancer patients during Covid-19 pandemic.
Clin Transl Radiat Oncol
September 2021
Article Synopsis
- The COVID-19 pandemic led to significant changes in head and neck oncology practices in the UK, with varying responses from different medical centers due to delayed guidelines.
- A multi-centre survey by the NCRI aimed to examine standard practices before and during the pandemic, focusing on treatment modifications related to feeding tubes, radiotherapy, and chemotherapy.
- The survey found that most participating centers made at least one modification, including changes in radiation treatment schedules and the cessation or adjustment of chemotherapy protocols, reflecting a shift to adapt to the pandemic's challenges.
Nivolumab is an anti-PD-1 monoclonal antibody currently used as immunotherapy for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with evidence of disease progression after platinum-based chemotherapy. This study evaluates real-world safety and treatment outcomes of non-trial nivolumab use. A retrospective multicenter cohort study of patients with recurrent/metastatic HNSCC treated with nivolumab between January 2017 and March 2020 was performed.
View Article and Find Full Text PDFBackground: Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence.
Patients And Methods: Patients with resected AJCC stage IIB, IIC and III cutaneous melanoma were randomised to receive either adjuvant bevacizumab (7.